ARC 183

Drug Profile

ARC 183

Latest Information Update: 26 Sep 2005

Price : $50

At a glance

  • Originator Archemix Corporation
  • Class Anticoagulants; Antithrombotics
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Thrombosis

Most Recent Events

  • 21 Sep 2005 Discontinued - Phase-I for Thrombosis in USA (unspecified route)
  • 17 Aug 2005 This programme is still in active development - (BIO-2005)
  • 09 Aug 2004 Phase-I clinical trials in Thrombosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top